Newsletter | April 8, 2020

04.08.20 -- Strategies To Address Viral Vector Manufacturing

Strategies To Address Viral Vector Manufacturing

Viral vectors have the potential to address unmet vaccines and there is currently a shortage in manufacturing capacity. Companies pursuing vaccine manufacturing as well as gene therapies must figure out a way to close the gap.

For many, this means facing a build versus buy capacity decision. Read the article to see why accelerating the production of viral-vector based therapy requires you to understand:

  • The strategies available to address the viral vector manufacturing shortage
  • How to select the most cost-effective solution for your next-generation therapeutic
Read the Article
Why did I get this? From time to time, we hand-pick articles that we feel may be of interest to you based on the content you’ve read on Outsourced Pharma. We hope you enjoy these pieces and we welcome feedback on how we can improve our editorial offerings.
This newsletter is being sent to {{lead.Email Address}}. If you need to update your preferences, please visit your user profile. To cancel your subscription to the newsletter, please opt out here.

© Copyright 2020 {{my.Member_Addr}}. All rights reserved. All product names contained herein are the trademarks of their respective holders.